/ Press Release / AAFA Statement on Asthma Inhaler Price Caps

AAFA Statement on Asthma Inhaler Price Caps

Mar 8, 2024 | Press Release

Patient advocacy group applauds efforts to make asthma medicine more affordable

Washington, D.C., March 8, 2024 – The Asthma and Allergy Foundation of America (AAFA) is leading advocacy efforts to change the drug pricing ecosystem and to make medicines more affordable and accessible for the 27 million people in the United States with asthma.

Boehringer Ingelheim announced it will cap out-of-pocket costs of its COPD and asthma inhaler portfolio at $35 per month for patients who have commercial insurance or no insurance.

“The announced price cap from Boehringer Ingelheim is a step toward improving access to essential asthma medicine and demonstrates that the voice of the asthma patient community is being heard,” states Kenneth Mendez, president and CEO of AAFA. “AAFA will continue to advocate that all stakeholders in the drug pricing ecosystem take steps to improve affordability and access for life-saving medicines.”

Last fall, AAFA shared patient stories and its Asthma Disparities in America report with the Senate Health, Education, Labor, and Pensions (HELP) Committee which then launched an investigation into the high price of asthma inhalers early this year.

In addition to pharmaceutical manufacturers, pharmacy benefit managers, insurance companies, employers, and federal policies all affect the final price paid for medicines. Unfortunately, these complex layers often mean that the current system discriminates against people who need these drugs the most.

Differences in prevalence and mortality rates present startling evidence of racial disparities in asthma. Black and Hispanic individuals have higher rates of asthma and are more likely to be uninsured or underinsured. Deaths due to asthma—although decreasing overall—occur at a much higher rate in the Black and Puerto Rican populations than in the White population. Black individuals are nearly three times as likely to die from asthma than White individuals.

AAFA’s research indicates that when the cost of medicine becomes a barrier to treatment, people with asthma resort to rationing or simply discontinue use.

Access to asthma medications can save lives, reduce hospitalizations, and lower the more than $82 billion in annual costs to the U.S. economy from this chronic disease. But the U.S. health care system is complex, and often leaves patients with few affordable options.


Press Contact:
Andy Spears
Asthma and Allergy Foundation of America (AAFA)

About AAFA

Founded in 1953, AAFA is the oldest and largest non-profit patient organization dedicated to saving lives and reducing the burden of disease for people with asthma, allergies, and related conditions through research, education, advocacy, and support. AAFA offers extensive support for individuals and families affected by asthma and allergic diseases, such as food allergies and atopic dermatitis (eczema). Through its online patient support communities, network of regional chapters, and collaborations with community-based groups, AAFA empowers patients and their families by providing practical, evidence-based information and community programs and services. AAFA is the only asthma and allergy patient advocacy group that is certified to meet the standards of excellence set by the National Health Council. For more information, visit: